Title
The effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease The effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
conferenceObject
Publication
Bologna :Monduzzi, [*]
Subject
Human medicine
Source (book)
Proceedings 9th Asian Pacific Congress of Nephrology (16-20 February 2003)
ISBN
88-323-3101-2
ISI
000182539200037
Carrier
E
Target language
English (eng)
Affiliation
University of Antwerp
Abstract
Lanthanum carbonate (Fosrenol(TM), Shire Pharmaceuticals) is a novel treatment for hyperphosphataemia. In this open-label study, we compared the effects of lanthanum carbonate and calcium carbonate on bone in dialysis patients. Paired bone biopsies were taken, at baseline and after 1 year of treatment, in 33 lanthanum- and 30 calcium-treated patients. Serum phosphate levels were well controlled in both groups and lanthanum carbonate was well tolerated. After 1 year of lanthanum carbonate treatment, five of seven patients with low bone turnover at baseline and four of five with hyperparathyroidism developed a more normal bone turnover. Only one; lanthanum patient developed adynamic bone compared with six in the calcium group. Analyses of data so far indicate that lanthanum carbonate does not have any adverse effects on bone.
E-info
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000182539200037&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000182539200037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle